Long-Term Safety and Efficacy of Pure Laparoscopic Donor Hepatectomy in Pediatric Living Donor Liver Transplantation

Wan-Joon Kim,¹ Ki-Hun Kim,² Hwui-Dong Cho,² Jung-Man Namgoong,³ Shin Hwang,² Jeong-Ik Park,⁴ and Sung-Gyu Lee²

¹Division of Hepatobiliary Pancreatic Surgery, Department of Surgery, Korea University Guro Hospital, Korea University Medical College, Seoul, Republic of Korea; ²Division of Hepatobiliary and Liver Transplantation, Department of Surgery, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea; ³Division of Pediatric Surgery, Department of Surgery, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea; and ⁴Department of Surgery, Haeundae Paik Hospital, Inje University, College of Medicine, Busan, Korea

Laparoscopic living donor hepatectomy for transplantation has been well established over the past decade. This study aimed to assess its safety and feasibility in pediatric living donor liver transplantation (LDLT) by comparing the surgical and long-term survival outcomes on both the donor and recipient sides between open and laparoscopic groups. The medical records of 100 patients (\leq 17 years old) who underwent ABO-compatible LDLT using a left lateral liver graft between May 2008 and June 2016 were analyzed. A total of 31 donors who underwent pure laparoscopic hepatectomy and their corresponding recipients were included in the study; 69 patients who underwent open living donor hepatectomy during the same period were included as a comparison group. To overcome bias from the different distributions of covariables among the patients in the 2 study groups, a 1:1 propensity score matching analysis was performed. The mean follow-up periods were 92.9 and 92.7 months in the open and laparoscopic group (8.1 days) than in the open group (10.6 days; P < 0.001). Overall, the surgical complications in the donors and overall survival rate of recipients did not differ between the groups. Our data suggest that the laparoscopic environment was not associated with long-term graft survival during pediatric LDLT. In addition, the laparoscopic approach for the donors did not adversely affect the corresponding recipient's outcome. Laparoscopic left lateral sectionectomy for living donors is a safe, feasible, and reproducible procedure for pediatric liver transplantation.

Liver Transplantation 27 513–524 2021 AASLD. Received June 8, 2020; accepted September 22, 2020.

SEE EDITORIAL ON PAGE 482

Liver transplantation is the most definitive treatment for children with end-stage liver disease. In general, the indications for liver transplantation in children include

Abbreviations: BMI, body mass index; BSA, body surface area; HVOO, hepatic venous outflow obstruction; INR, international normalized ratio; LDH, laparoscopic donor hepatectomy; LDLT, living donor liver transplantation; LFT, liver function test; LGA, left gastric artery; LHA, left hepatic artery; ODH, open donor hepatectomy; PELD, pediatric end-stage liver disease; PSM, propensity score matching; RHA, right hepatic artery; SMA, superior mesenteric artery. cholestatic disease, metabolic disorders, malignancy, chronic hepatitis, and acute liver failure attributed to viral infections or the effects of medication.

Progress in the management of immunosuppressive therapy suitable for children has been of key importance in improving survival rates after transplant procedures. The use of variant allografts has helped in overcoming the shortage of suitable donors for children. The evolution of donor methods and surgical techniques in graft implantation has also contributed to the success rate of pediatric living donor liver transplantation (LDLT).⁽¹⁻³⁾

After the introduction of laparoscopic hepatectomy, a sufficient number of case studies have demonstrated

that this procedure has similar survival outcomes as laparotomy. Thus, laparoscopic hepatectomy has been vigorously applied in the field of transplantation, beginning approximately 10 years ago until its current active implementation in various centers.⁽⁴⁻⁶⁾

Cherqui et al.⁽⁷⁾ first described laparoscopic left lateral sectionectomy for an adult-to-pediatric donation, and the procedure is now considered an acceptable practice. However, because pediatric LDLT is performed only at highly specialized centers, data on the safety of laparoscopic procedures for liver donation have not been accumulated. Therefore, we aimed to assess the safety of the procedure in children, including the surgical complications and survival outcomes after LDLT using a left lateral liver graft, to evaluate and compare pure laparoscopic donor hepatectomy (LDH) and open donor hepatectomy (ODH) in a high-volume LDLT center. In addition, the long-term graft survival outcome was also investigated to determine the effects of the laparoscopic environment represented by carbon dioxide pneumoperitoneum.

Patients and Methods

A retrospective, observational, and single-center study was conducted after obtaining written informed consent from each patient and acquiring approval from the ethics committee of Asan Medical Center. We analyzed the medical records of 100 patients (\leq 17 years old) who underwent ABO-compatible LDLT between May 2008 and June 2016. Of the 100 patients, 69 underwent ODH, and 31 underwent pure LDH.

Address reprint requests to Ki-Hun Kim, M.D., Ph.D., Division of Hepatobiliary and Liver Transplantation, Department of Surgery, Asan Medical Center, University of Ulsan College of Medicine, 88 Olympic-ro 43 gil, Songpa-gu, Seoul 05505, Republic of Korea. Telephone: +82-2-3010-3495; FAX: +82-2-3010-6701; E-mail: kbkim620@amc.seoul.kr

Additional supporting information may be found in the online version of this article.

Copyright © 2020 The Authors. Liver Transplantation published by Wiley Periodicals LLC on behalf of American Association for the Study of Liver Diseases. This is an open access article under the terms of the Creative Commons Attribution-NonCommercial License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.

View this article online at wileyonlinelibrary.com

DOI 10.1002/lt.25910

Potential conflict of interest: Nothing to report.

Pediatric LDLT using an open approach was first performed at Asan Medical Center in December 1994. A total of 133 cases of pediatric LDLT using an open donor liver graft were performed from December 1994 to December 2007. Later, with the accumulation of experience with laparoscopic surgery, LDH began to be used for pediatric LDLT in 2008. Donors were provided a thorough explanation of the advantages and disadvantages of ODH and LDH, after which they decided on their preferred type of operation. No specific exclusion criteria have been established since then, and anatomical abnormalities such as a left hepatic artery arising from the left gastric artery and a right posterior bile duct draining into the left hepatic duct have been shown not to interfere with the laparoscopic approach.

To minimize time bias, we collected and compared data from 2008 (when LDH was initially implemented) onward. In addition, to overcome bias from the different distributions of covariables among the patients in the 2 study groups, a propensity score matching (PSM) analysis was performed in a 1:1 ratio using the nearest-neighbor matching method for the following variables: diagnosis; recipient age, sex, body mass index (BMI), and body surface area (BSA); and donor sex, age, and BMI. Our study was approved by the Asan Medical Center institutional ethical board (approval no. 2020-0723).

DONOR PREPARATION

The donor's preoperative examination was performed twice in total. In the first stage, blood tests as well as a liver function test (LFT) and a computed tomography scan to measure the graft volume were performed. Subsequently, in the second stage, magnetic resonance cholangiography and the indocyanine green retention test after 15 minutes were performed to determine the detailed anatomy and accurate liver function. Liver biopsy was not performed if the donor's age was <30 years, the LFT result was normal, and mild fatty liver was suspected on the basis of imaging findings. When necessary, sonography-guided percutaneous liver biopsy was performed to obtain liver tissue and performed twice on the right and left lobes. A hepatobiliary scan was performed routinely on the fifth day after the operation. According to International Study Group of Liver Surgery classification,⁽⁸⁾ grade B (bile leakage requiring a change in patient clinical management [additional diagnostic or interventional procedures] but manageable without relaparotomy or a grade A bile leakage lasting for >1 week) was considered a surgical complication.

IMMUNOSUPPRESSION

The immunosuppressive protocol used at our institute includes tacrolimus, mycophenolate mofetil, and steroids. Basiliximab was administered at 12 mg/m² on posttransplant days 0 and 4. Tacrolimus was given at 0.0375 mg/kg twice a day and started on posttransplant day 1. Mycophenolate mofetil therapy was started preoperatively at 15 mg/kg a day and was continued for 6 months. Steroid administration was started intraoperatively and continued for 3 months with a lower dose.

OPEN LEFT LATERAL DONOR HEPATECTOMY

ODH was performed under general anesthesia with the patients in the supine position. Exploratory laparotomy was performed using a J-shaped or midline skin incision, and the left lateral section was drawn to the left of the round ligament after the dissection of the left triangular ligament. In a separate procedure on the hilar vasculature, the left hepatic artery and portal vein were exposed and isolated, with each vessel looped after dissection of the connective tissue. The hepatic parenchyma was divided along the right side of the falciform ligament by using an ultrasonic aspirator (Cavitron Ultrasonic Surgical Aspiratior [CUSA] Excel; Valleylab, Boulder, CO), and the pedicles to segment IV were divided without the Pringle maneuver. After the transection of the parenchyma, intraoperative cholangiography was used to divide the left hepatic duct between 2 radio-opaque rubber bands, tagged transversely on the proposed dividing site of the left hepatic duct by holding sutures. After the infusion of 5000 units of heparin, the left hepatic vein was divided using a vascular clamp, and the stump was closed with a 5-0 Prolene continuous suture (Ethicon, Johnson & Johnson, Somerville, NJ). Finally, the left lateral liver graft was procured at the completion of the recipient's surgery.

The graft was flushed on the back table with 1 or 2 L of a histidine-tryptophan-ketoglutarate solution (Odyssey Pharmaceuticals, East Hanover, NJ) through the left portal vein.

LAPAROSCOPIC LEFT LATERAL DONOR HEPATECTOMY

The surgical technique was similar to those described previously with few modifications.⁽⁹⁾ The left hepatic artery and portal vein were dissected and encircled with 2 vessel loops. The Pringle maneuver was

used during the parenchymal transection. The liver was transected using an alternating combination of a laparoscopic ultrasonic aspirator (CUSA Excel) and THUNDERBEAT (Olympus, Tokyo, Japan). The hepatic parenchyma was divided along the right side of the falciform ligament, and the pedicles to segment IV were divided. When the liver division reached the left hepatic vein, the left lateral sector was surrounded by a Jackson-Pratt drain line, which was passed under the left hepatic vein, portal vein, and hepatic artery, for a liver hanging maneuver.

The left bile duct was identified after intraoperative cholangiography using a mobile C-arm in which contrast was infused via the cystic duct through a cobra tube (Torcon NB Advantage catheter; Cook Medical, Bloomington, IN). After Hem-o-Lok (Weck Closure Systems, Research Triangle Park, NC) clipping at the target divide level, cholangiography was performed again to check whether the right duct was intact, and then the duct was resected.⁽¹⁰⁾ Finally, after the infusion of 5000 units of heparin, the left hepatic artery and left portal vein were clipped and divided using Hem-o-Lok clips. A unilateral linear stapler (30-mm Endo TA; US Surgical, Norwalk, CT) was used to cut the left hepatic vein. The graft was placed in an endo-bag that was inserted through a 12-mm trocar and retrieved through a 10-cm suprapubic incision site. After the graft was taken out of the body, a leaking test was performed using a methylene blue solution injected through a cobra tube inserted in the cystic duct. The graft was flushed on the back table with 1 or 2 L of a histidine-tryptophan-ketoglutarate solution (Odyssey Pharmaceuticals) through the left portal vein.

STATISTICAL ANALYSES

Data with a normal distribution are reported as mean \pm standard deviation. Variables not fitting a normal distribution are presented in the Result section as median (range). Continuous variables were compared using the Student *t* test if normally distributed; otherwise, the Mann-Whitney U test was used.

Categorical variables were compared using the chisquare test. The patients' overall and death-censored graft survival rates were estimated using the Kaplan-Meier method and compared with log-rank tests. Data were considered statistically significant at P values of <0.05. Multivariate models were manually built using a forward strategy. Statistical analyses were performed using SPSS version 22.0 for Windows (IBM Corp., Armonk, NY).

Results

DEMOGRAPHIC DATA AND SURGICAL OUTCOMES OF THE DONORS AND RECIPIENTS BEFORE PSM

In the ODH group, the ages, preoperative ventilator use, and preoperative pediatric end-stage liver disease (PELD) scores of the recipients were significantly different from those in the LDH group. The total ischemic time, including the warm and cold ischemic times of the graft, was not significantly different between the 2 groups. The overall surgical complication rate of the recipients also did not significantly differ between the 2 groups (Table 1).

For the donors, those in the LDH group were younger than those in the ODH group, and the

	ODH (n = 69)	LDH $(n = 31)$	Total (n = 100)	P Value
Sex				0.332
Male	36 (52.1)	12 (38.7)	48 (48.0)	
Female	33 (47.9)	19 (61.3)	52 (52.0)	
Age, months	51.6 ± 53.3	17.6 ± 27.3	41.8 ± 49.6	<0.001
BMI, kg/m ²	17.2 ± 3.2	17.6 ± 7.1	17.3 ± 4.6	0.729
BSA, m ²	0.7 ± 0.4	0.5 ± 0.2	0.6 ± 0.4	< 0.001
Prothrombin time, INR	2.3 ± 1.3	1.4 ± 0.5	2.0 ± 1.2	< 0.001
Total bilirubin, mg/dL	15.8 ± 11.4	13.2 ± 9.3	15.0 ± 10.9	0.267
PELD score	21.0 ± 11.0	14.0 ± 7.4	18.9 ± 10.5	< 0.001
Indication for transplant				<0.001
Biliary atresia	17 (27.6)	23 (74.2)		
Primary sclerosing cholangitis	1 (1.3)	0 (0.0)		
Hepatoblastoma	7 (13.2)	2 (6.5)		
Wilson's disease	6 (7.9)	0 (0.0)		
Hepatocellular carcinoma	0 (0.0)	1 (3.2)		
Fulminant	28 (36.8)	4 (12.9)		
Others	10 (13.2)	1 (3.2)		
Length of operation time, minutes	573.4 ± 100.4	581.2 ± 93.7	575.6 <u>+</u> 98.2	0.710
Surgical complication				
Biliary stricture				0.702
No	67 (97.1)	29 (93.5)	96 (96.0)	
Yes	2 (2.9)	2 (6.5)	4 (4.0)	
Biliary leakage				0.684
No	66 (95.6)	28 (90.3)	94 (94.0)	
Yes	3 (4.4)	3 (9.7)	6 (6.0)	
Hepatic artery thrombosis				0.901
No	68 (98.5)	31 (100.0)	99 (99.0)	
Yes	1 (1.5)	0 (0.0)	1 (1.0)	
HVOO				0.459
No	65 (94.2)	31 (100.0)	96 (96.0)	
Yes	4 (5.8)	0 (0.0)	4 (4.0)	
Portal vein stenosis				0.186
No	64 (92.7)	27 (87.1)	91 (91.0)	
Yes	5 (7.3)	4 (12.9)	9 (9.0)	
Rejection episode				1.000
No	57 (82.6)	24 (77.4)	81 (81.0)	
Yes	12 (17.4)	7 (22.6)	19 (19.0)	

TABLE 1. Demographic Data and Surgical Outcomes of Recipients Before PSM

NOTE: Data are provided as n (%) or mean \pm standard deviation.

516 | ORIGINAL ARTICLE

postoperative hospital stay was shorter in the LDH group. The donor operation time was longer in the LDH group. The postoperative peak levels of aspartate aminotransferase, alanine aminotransferase, and total bilirubin showed no significant differences between the 2 groups. The overall postoperative complication rate was higher in the ODH group (Table 2).

CLINICOPATHOLOGICAL FEATURES AND SURGICAL OUTCOMES OF THE RECIPIENTS AFTER PSM

After PSM, the ODH and LDH groups were well balanced (31 cases each). The mean follow-up period was 92.9 months in the ODH group and 92.7 months

	ODH $(n = 69)$	LDH $(n = 31)$	Total (n = 100)	P Value
Sex				0.031
Male	32 (46.3)	7 (22.6)	39 (39.0)	
Female	37 (53.7)	24 (77.4)	61 (61.0)	
Age, years	34.8 ± 6.7	31.7 ± 6.0	33.9 <u>+</u> 6.6	0.031
BMI, kg/m ²	23.4 ± 3.4	22.8 <u>+</u> 3.7	23.2 ± 3.4	0.433
Graft weight, g	311.1 <u>+</u> 125.1	265.1 <u>+</u> 78.9	297.8 ± 115.2	0.025
Artery anatomy				0.088
Classic	59 (85.5)	27 (87.1)	86 (86.0)	
Replaced RHA from SMA	2 (2.9)	3 (9.7)	5 (5.0)	
Replaced LHA from LGA	5 (7.2)	1 (3.2)	6 (6.0)	
Accessory LHA from LGA	3 (4.3)	0 (0.0)	3 (3.0)	
Portal vein anatomy				0.422
Type 1	61 (88.4)	29 (93.5)	90 (90.0)	
Туре 2	4 (5.8)	2 (6.5)	6 (6.0)	
Туре З	4 (5.8)	0 (0.0)	4 (4.0)	
Bile duct anatomy*				0.447
Type 1	57 (82.6)	28 (90.3)	85 (85.0)	
Туре 2	3 (4.3)	0 (0.0)	3 (3.0)	
Туре Зb	6 (8.6)	3 (9.7)	9 (9.0)	
Type 4b	3 (4.3)	0 (0.0)	3 (3.0)	
Cold ischemic time, minutes	44.6 ± 22.8	50.2 ± 24.1	46.2 ± 23.2	0.262
Warm ischemic time, minutes ⁺	5.6 ± 1.9	6.8 ± 3.6	6.2 ± 2.8	0.780
Total ischemic time, minutes	75.2 ± 26.1	81.3 ± 23.2	77.0 ± 25.3	0.266
Number of arteries				0.508
1	67 (97.1)	30 (96.8)	97 (97.0)	
2	2 (2.9)	1 (3.2)	3 (3.0)	
Number of bile duct openings				0.409
1	60 (86.9)	29 (93.5)	89 (89.0)	
2	9 (13.1)	2 (6.5)	11 (11.0)	
Length of operation time, minutes	349.4 ± 55.1	383.0 ± 64.0	359.2 ± 59.5	0.008
Length of postoperative hospital stay, days	11.3 ± 2.4	8.1 ± 2.7	10.3 ± 2.9	<0.001
Surgical complication				0.025
Wound problem	2 (2.8)	0 (0.0)	2 (2.0)	
Bile leakage	1 (1.4)	0 (0.0)	1 (1.0)	
Pleural effusion	2 (2.6)	0 (0.0)	2 (2.0)	
Fluid collection	3 (3.9)	0 (0.0)	3 (3.0)	
None	61 (88.4)	31 (100.0)	92 (92.0)	

TABLE 2. Demographic Data and Surgical Outcomes of Donors and Grafts Before PSM

NOTE: Data are provided as n (%) or mean \pm standard deviation.

*Classification of biliary tree anatomy variation according to Varotti et al.⁽²⁶⁾

[†]Time to retrieve a graft from the abdomen.

in the LDH group. The most common cause of surgical treatment in both groups was biliary atresia. The mean PELD score was 18.2 in the ODH group and 14.0 in the LDH group. The cold ischemic time was 42.2 \pm 19.1 minutes in the ODH group and 50.2 ± 24.1 minutes in the LDH group. The warm ischemic time was 5.6 ± 1.9 minutes in the ODH group and 6.8 ± 3.6 minutes in the LDH group. Portal vein stenting was performed because of postoperative portal vein stenosis in 5 recipients in the ODH group and 4 recipients in the LDH group. During the follow-up period, 5 recipients in the ODH group and 7 recipients in the LDH group experienced rejection episodes. The overall surgical complication rate of the recipients did not differ between the 2 groups (Table 3).

	ODH (n = 31)	LDH $(n = 31)$	P Value
Sex			1.000
Male	12 (38.7)	12 (38.7)	
Female	19 (61.3)	19 (61.3)	
Age, months	29.7 ± 38.0	17.6 ± 27.3	0.157
BMI, kg/m ²	17.7 ± 3.1	17.6 ± 7.1	0.929
BSA, m ²	0.6 ± 0.4	0.5 ± 0.2	0.052
Prothrombin time, INR	1.9 ± 1.0	1.4 ± 0.5	0.065
Total bilirubin, mg/dL	15.0 ± 8.9	13.2 ± 9.3	0.447
PELD score	18.2 ± 11.0	14.0 ± 7.4	0.082
Indication for transplant			0.059
Biliary atresia	13 (41.9)	23 (74.2)	
Primary sclerosing cholangitis	0 (0.0)	0 (0.0)	
Hepatoblastoma	6 (19.4)	2 (6.5)	
Wilson's disease	1 (3.2)	0 (0.0)	
Hepatocellular carcinoma	0 (0.0)	1 (3.2)	
Fulminant	7 (22.6)	4 (12.9)	
Others	4 (12.9)	1 (3.2)	
Length of operation time, minutes	577.8 ± 87.2	581.2 ± 93.7	0.884
Surgical complication			
Biliary stricture			0.902
No	30 (96.8)	29 (93.5)	
Yes	1 (3.2)	2 (6.5)	
Biliary leakage			0.237
No	31 (100.0)	28 (90.3)	
Yes	0 (0.0)	3 (9.7)	
Hepatic artery thrombosis			1.000
No	31 (100.0)	31 (100.0)	
Yes	0 (0.0)	0 (0.0)	
HVOO			1.000
No	31 (100.0)	31 (100.0)	
Yes	0 (0.0)	0 (0.0)	
Portal vein stenosis			0.906
No	26 (83.9)	27 (87.1)	
Yes	5 (16.1)	4 (12.9)	
Rejection episode			0.748
No	26 (83.9)	24 (77.4)	
Yes	5 (16.1)	7 (22.6)	

TABLE 3.	Clinicopathological	Features and Surgical	Outcomes of Recipient	ts After PSM

NOTE: Data are provided as n (%) or mean \pm standard deviation.

Two children in the ODH group and 1 child in the LDH group died during the follow-up period. In the ODH group, both children died after graft dysfunction secondary to a rejection episode. In the mortality case in the LDH group, the patient died of uncontrolled sepsis. The overall recipient mortality rates were 6.4% (n = 2) and 3.2% (n = 1) in the ODH and LDH groups, respectively. The 1-, 3-, and 5-year overall survival rates were consistently 93.6% for all time points in the ODH group, and 96.8%, 93.6%, and 93.6% in the LDH group (P = 0.557). The 1-, 3-, and 5-year death-censored graft survival rates were 93.6%, 93.6%, and 93.6% in the ODH group and 100%, 100%, and 100% in the LDH group, respectively (P = 0.157; Fig. 1).

PERIOPERATIVE AND POSTOPERATIVE SURGICAL OUTCOMES OF THE DONORS AND GRAFTS AFTER PSM

A replaced right hepatic artery arising from the superior mesentery artery was observed in 1 patient in the ODH group and 3 patients in the LDH group. In contrast, a replaced left hepatic artery arising from the left gastric artery was observed in 2 patients in the ODH group and 1 patient in the LDH group. A type 2 portal vein was observed in 3 patients in the ODH group and 3 patients in the LDH group, whereas a type 3 portal vein was observed in 2 patients in the ODH group and in 1 patient in the LDH group. In terms of the biliary



system, types 2 (trifurcation) and 4b branching (the right posterior duct into the common hepatic duct) were observed in 2 cases and 1 case in the ODH group, respectively, whereas type 3b branching (the right posterior duct into the left hepatic duct) was observed in 3 cases in each group.

The mean operation time was 360.1 minutes in the ODH group and 383.0 minutes in the LDH group, with no significant difference between the 2 groups (P = 0.146).

The postoperative peak aspartate aminotransferase, alanine aminotransferase, and bilirubin levels were not different between the 2 groups. However, the post-operative hospital stay was significantly shorter in the LDH group (8.1 days) than in the ODH group (10.6 days; P < 0.001).

Donor complications with a Clavien-Dindo grade higher than 3 were observed in 2 cases in the ODH group, whereas no such complications were observed in the LDH group. One case involved a wound problem treated with wound repair under local anesthesia, and the other case needed percutaneous drainage performed with fluid collection at the resection site after the operation (Table 4).

Discussion

The general advantages of laparoscopic surgery are known for shortened rehabilitation period, improved cosmetic outcome, and high precision and visualization during the procedure.⁽¹¹⁻¹³⁾

The first laparoscopic liver resection was reported nearly 25 years ago. The worldwide literature reports approximately 3000 laparoscopic liver resections, three-quarters of which were performed from 2006 onward. The results suggest that in experienced centers, laparoscopic liver resection can be performed with equal safety and oncological efficacy as open surgery.⁽¹⁴⁻¹⁶⁾

Despite the surgical difficulties, the implementation of LDH is expanding across high-volume LDLT centers owing to the accumulation of experience and advances in instrument development. National and international registries could potentially provide meaningful data by allowing for a risk-benefit analysis of laparoscopic procedures for pediatric liver transplantation. Well-organized articles that discuss the technique have been published from various centers.⁽¹⁷⁻¹⁹⁾

Moreover, in 2011, we also published an initial study on the feasibility of laparoscopic donor left

lateral sectionectomy.⁽⁹⁾ This study builds on the aforementioned study to validate long-term patient and graft survival outcomes, including detailed surgical complications, through a larger number of patients. To the best of our knowledge, this study has the longest follow-up period among the studies about pediatric LDLT using the laparoscopic technique.

In 2015, an interesting article that validated the usefulness of laparoscopic lateral suspension in pediatric LDLT by comparing postoperative outcomes with those of laparoscopic donor nephrectomy (a well-standardized and globally accepted procedure) was published.⁽¹⁹⁾ In that article, Soubrane et al. reported 21 cases (16.9%) of surgical complications, including 6 cases of Clavien-Dindo grade 3 or higher, in 124 liver donors who underwent laparoscopic lateral suspension. Among the cases, 4 reoperations (3%) were reported.

In our present study, we identified no donor complications in the LDH group. The mean postoperative hospital stay of the donors was significantly shorter in the laparoscopic group (8.1 days) than in the open group (10.6 days; P < 0.001). The reason for the relatively longer hospital stays in Korea than in other countries such as the United States is probably the Korean insurance system. Owing to the national health insurance system, Korean patients tend to be hospitalized for long periods with low medical expenses. This is thought to be a major factor in the long hospitalization period of donors without special complications.

The stability of laparoscopic graft applications in pediatric LDLT should be validated in terms of surgical outcomes in recipients, including long-term graft outcomes. In 2018, Broering et al.⁽²⁰⁾ reported that 2 portal vein stenoses (2.8%), 1 hepatic artery thrombus (1.4%), and 6 biliary strictures (8.3%) occurred in the laparoscopic technique group (n = 72). In addition, 1 case of retransplantation attributed to chronic rejection episodes was reported in each of the open and laparoscopic technique groups.

In our study, 4 portal vein stenoses (12.9%), 2 biliary strictures (6.5%), and 3 episodes of biliary leakage (9.7%) occurred in the LDH group, with no significant differences from those in the ODH group. Our center does not routinely perform portal vein widening as the graft portal vein is considered a "no-touch" area. Alternatively, we performed wedge-patch venoplasty in cases with an exceptionally narrow graft portal vein to cope with the portal vein size mismatch in LDLT.⁽¹⁸⁾

Most centers that perform pediatric liver transplantation have been challenged by the fatal complication

Sex 0.271 Mole 12 (38.7) 7 (22.6) Female 19 (61.3) 24 (77.4) Age, years 34.1 ± 4.7 31.7 ± 6.0 0.089 BMI, Kym ² 23.4 ± 3.4 22.8 ± 3.7 0.495 Graft weight, g 269.9 ± 87.3 265.1 ± 78.9 0.821 Arbey anatomy 0.509 0.509 0.509 Clossic 28 (90.3) 27 (87.1) 84.1 ± 78.9 0.821 Replaced IPA from SMA 1 (3.2) 3 (9.7) 84.1 ± 78.9 0.509 Clossic 28 (90.3) 27 (87.1) 29 (93.5) 10.20 0.000 Protein anatomy 0.500 0 (0.0) 0 (0.0) 0.000 88.1 ± 2.2 0.530 Type 1 27 (87.1) 29 (93.5) 10.00 10.00 1000		ODH (n = 31)	LDH $(n = 31)$	P Value
Male 12 (38.7) 7 (22.6) Fermole 19 (61.3) 24 (77.4) Age. years 33.1 ± 4.7 31.7 ± 6.0 0.089 BMI, kg/m ² 23.4 ± 3.4 22.8 ± 3.7 0.495 Graft weight, g 23.9 ± 5.7.3 22.8 ± 3.7 0.495 Arley onatomy 0.009 0.821 0.821 Relaced IMA from SMA 1 (2.2) 3 (9.7) 8.93 Replaced IMA from LGA 0 (0.0) 0 (0.0) 0 (0.0) Polito entime Monit LGA 0 (0.0) 0 (0.0) 0.830 Type 1 27 (87.1) 29 (93.5) 0.900 Pipe 2 3 (9.7) 2 (6.5) 0.000 Type 3 1.6.22 0.000 0.900 Type 4 1 (3.2) 0 (0.0) 0.900 Type 4 1 (3.2) 0 (0.0) 0.900 Type 4 1 (3.2) 0 (0.0) 0.900 Type 5 1 (3.2) 0 (0.0) 0.900 Type 4 1 (3.2) 0.900 0.900 Typ	Sex			0.271
Fendle 19 (61.3) 24 (77.4) Age, years 34.1 ± 4.7 31.7 ± 6.0 0.089 BM, kg/m ² 23.4 ± 3.4 22.8 ± 3.7 0.495 Graft weight, g 269.9 ± 87.3 265.1 ± 78.9 0.821 Arter, anotomy 0.509 27 (87.1) 0.609 Clossic 28 (90.3) 27 (87.1) 29 (93.5) Replaced IMA from IGA 2 (6.5) 1 (3.2) 0.00 Portal vein anatomy 0.000 0.001 0.530 Type 1 27 (87.1) 29 (93.5) 1 Type 2 3 (9.7) 2 (6.5) 0.001 Type 3 1 (3.2) 0.00 0.001 Type 1 25 (80.6) 2 (8.0.3) 2 (9.0.3) Type 3 3 (9.7) 3 (9.7) 3 (9.7) Type 4b 1 (3.2) 0 (0.0) 0 (0.0) Type 3b 3 (9.7) 3 (9.7) 3 (9.7) Type 4b 1 (3.2) 0 (0.0) 0 (0.0) Type 4b 1 (3.2) 0 (0.0)	Male	12 (38.7)	7 (22.6)	
Åge, years 34.1 ± 4.7 31.7 ± 6.0 0.089 BMI, Kym ² 23.4 ± 3.4 22.8 ± 3.7 0.495 Graft weight, g 266.9 ± 67.3 26.6 ± 7.8.9 0.821 Artery anatomy 0.509 0.509 0.509 Clossic 28 (90.3) 27 (87.1) 0.509 Replaced ItAr from IGA 1 (3.2) 3 (9.7) 2 (5.5) Accessony LHA from IGA 0 (0.0) 0 (0.0) 0 (0.0) Portal wein anatomy 29 (93.5) 1 (3.2) 0 (0.0) Type 1 29 (80.6) 28 (90.3) 1 (3.2) 0 (0.0) Type 3 1 (3.2) 0 (0.0) 0 (0.0) 0 (0.0) Type 4 2 (6.5) 0 (0.0) 0 (0.0) 0 (0.0) Type 3 3 (9.7) 3 (9.7) 0 (0.0) 0 (0.0) Type 4 1 (3.2) 0 (0.0) 0 (0.0) 0 (0.0) Type 3 3 (9.7) 3 (9.7) 0 (0.0) 0 (0.0) Type 4 2 (6.5) 0 (0.0) 0 (0.0) 0 (0.0)	Female	19 (61.3)	24 (77.4)	
BMI, kg/m² 23.4 ± 3.4 22.8 ± 3.7 0.495 Graft weight, g 26.9 ± 87.3 26.5 1 ± 78.9 0.821 Arlery onatomy 0.509 27.67.1) 0.509 Classic 28.90.3) 27.67.1) 7.000 Replaced HA from SMA 1.6.2.2 3.67.7) 7.000 Replaced HA from LGA 0.0.0 0.00 0.00 Portal vein anatomy 0.530 7.000 0.00 Accessory LHA from LGA 0.0.0 2.000.0 0.00 Type 1 27.67.7) 2.900.50 0.000 Type 3 1.0.3.2 0.000 0.00 Type 1 25.600.6 28.60.3) 0.00 Type 2 2.66.5 0.00.0 0.00 Type 3 3.07.7 3.07.7 0.156 Warm ischemic time, minutes 42.2 ± 19.1 50.2 ± 24.1 0.156 Warm ischemic time, minutes 28.07.3 3.000.6 1.000 2 3.07.7 2.65.7 0.000 0.000 2 3.0.0	Age, years	34.1 ± 4.7	31.7 ± 6.0	0.089
Graft weight, g 269.9 ± 87.3 265.1 ± 78.9 0.821 Arter randomy 0.509 Classic 28 (90.3) 27 (87.1) Replaced HA from SMA 1 (3.2) 3 (9.7) Replaced HA from IGA 2 (6.5) 1 (3.2) Accessory LHA from LGA 0 (0.0) 0 (0.0) Portal via natomy 0.500 Type 1 27 (87.1) 29 (93.5) Type 2 3 (9.7) 2 (6.5) Type 1 25 (80.6) 28 (90.3) Type 1 26 (80.6) 28 (90.3) Type 1 26 (80.6) 28 (90.3) Type 2 2 (6.5) 0 (0.0) Type 3 3 (9.7) 3 (9.7) Type 4b 1 (3.2) 0 (0.0) Clai lischemic time, minutes 5 5 ± 1.8 6.8 ± 3.6 0.518 Total ischemic time, minutes 7 5 ± 1.8 6.8 ± 3.6 0.518 Number of arteries 0.508 0 0.508 1 2 8 (90.3) 30 (96.6) 0.512 2 3 (9.7)	BMI, kg/m ²	23.4 ± 3.4	22.8 ± 3.7	0.495
Artery anatomy 0.0509 Classic 26 (90.3) 37 (87.1) Replaced HM from SMA 1 (3.2) 3 (9.7) Replaced HM from IGA 2 (6.5) 1 (3.2) Accessory HM from IGA 0 (0.0) 0 (0.0) Portal vein anatomy 0.00, 0 (0.0) Type 1 27 (87.1) 29 (93.5) Type 2 3 (9.7) 2 (6.5) Type 3 0 (0.0) 0 Bile duct anatomy 0 (3.2) 0 (0.0) Type 1 25 (80.6) 28 (90.3) 0 Type 2 2 (6.5) 0 (0.0) 0 Type 3 3 (9.7) 3 (9.7) 3 (9.7) Type 4 1 (3.2) 0 (0.0) 0 Cold ischemic time, minutes 42 2 ± 19.1 50 2 ± 24.1 0.156 Number of arteries 1 (3.2) 0 (0.0) 0 Number of arteries 1 (3.2) 0 (0.0) 0 1 28 (90.3) 30 (96.8) 1 0 2 3 (9.7) 2 (6.5)	Graft weight, g	269.9 ± 87.3	265.1 ± 78.9	0.821
Classic 28 (90.3) 27 (87.1) Replaced RM from SMA 1 (3.2) 3 (9.7) Replaced IMA from IGA 2 (6.5) 1 (3.2) Accessory LMA from IGA 0 (0.0) 0 (0.0) Portal vein onotomy 0 (0.0) 0 (0.0) Prope 1 27 (87.1) 29 (93.5) Type 2 3 (9.7) 2 (6.5) Type 1 25 (80.6) 28 (90.3) Type 2 2 (6.5) 0 (0.0) Type 3b 3 (9.7) 3 (9.7) Type 4b 1 (3.2) 0 (0.0) Cold ischemic time, minutes 5.5 ± 1.8 6.8 ± 3.6 0.518 Total ischemic time, minutes 5.5 ± 1.8 6.8 ± 3.6 0.518 Total ischemic time, minutes 7.2 ± 20.4 81.3 ± 23.2 0.105 Number of arteries 7.2 ± 20.4 81.3 ± 23.2 0.105 Number of arteries 3 (9.7) 1 (3.2) 0.004 1 28 (90.3) 29 (93.5) 2 0.156 Statistime, minutes 3 (9.7) 2 (6.5) 0.001	Artery anatomy			0.509
Replaced RHA from SMA 1 (3.2) 3 (9.7) Replaced LHA from LGA 2 (6.5) 1 (3.2) Accessory LHA from LGA 0 (0.0) 0 (0.0) Portal vian anatomy 0.300 0 (0.0) Type 1 27 (87.1) 29 (93.5) 0 (0.0) Type 2 3 (9.7) 2 (6.5) 0 (0.0) Bile duct anatomy 0.300 0 (0.0) 0.300 Type 3 1 (3.2) 0 (0.0) 0 (0.0) Type 1 25 (80.6) 28 (90.3) 0 (0.0) Type 2 2 (6.5) 0 (0.0) 0 (0.0) Type 4b 1 (3.2) 0 (0.0) 0 (0.0) Cold ischemic time, minutes 42 2 ± 19.1 50 2 ± 24.1 0.156 Warm ischemic time, minutes 72 1 ± 20.4 81.3 ± 23.2 0.105 Variat Schemic time, minutes 72 1 ± 20.4 81.3 ± 23.2 0.105 Variat Schemic time, minutes 72 1 ± 20.4 83.3 ± 64.0 0.146 Legy 10 for orderies 0.900 0.900 0.900 2 3 (9.7)	Classic	28 (90.3)	27 (87.1)	
Replaced LHA from LGA 2 (6.5) 1 (3.2) Accessory LHA from LGA 0 (0.0) 0 (0.0) Portal vein anatomy 0.530 Type 1 27 (87.1) 29 (93.5) Type 2 3 (9.7) 2 (6.5) Type 3 1 (3.2) 0 (0.0) Bile duct anatomy 0 (3.2) 0 (0.0) Type 3 2 (6.5) 0 (0.0) Type 2 2 (6.5) 0 (0.0) Type 3 3 (9.7) 3 (9.7) Type 4b 1 (3.2) 0 (0.0) Type 3b 3 (9.7) 3 (9.7) Type 4b 1 (3.2) 0 (0.0) Cold ischemic time, minutes 42.2 ± 19.1 50.2 ± 24.1 0.156 Warm ischemic time, minutes 7.5 ± 1.8 6.8 ± 3.6 0.518 Total ischemic time, minutes 7.1 ± 20.4 81.3 ± 23.2 0.105 Number of arterise 0.508 2 0.56 2 3 (9.7) 1 (3.2) 0.56 2 3 (9.7) 2 (6.5) 0.56 2	Replaced RHA from SMA	1 (3.2)	3 (9.7)	
Accessory LHA from LGA 0 (0.0) 0 (0.0) Portly vien anatomy 0 (0.0) 0 (0.0) Type 1 27 (87.1) 29 (93.5) Type 3 1 (3.2) 0 (0.0) Bile duct anatomy 0 (0.0) 0 (0.0) Type 1 25 (80.6) 28 (90.3) Type 1 2 (6.5) 0 (0.0) Type 3b 3 (9.7) 3 (9.7) Type 4b 1 (3.2) 0 (0.0) Cold ischemic time, minutes* 5.5 ± 1.8 6.8 ± 3.6 0.518 Total ischemic time, minutes* 5.2 ± 1.20.4 0.1065 0.000 Number of arteries 2.8 (90.3) 30 (96.8) 0.105 Number of bile duct openings 2.8 (90.3) 29 (93.5) 0.104 Length of postoperative hospital stay, days 0.60.1 ± 58.3 383.0 ± 64.0 0.146 Length of postoperative hospital stay, days 0.60.1 ± 58.3 383.0 ± 64.0 0.146 Length of postoperative hospital stay, days 0.60.1 ± 58.3 383.0 ± 64.0 0.146 Length of postoperative hospital stay, days 0.60.0 <t< td=""><td>Replaced LHA from LGA</td><td>2 (6.5)</td><td>1 (3.2)</td><td></td></t<>	Replaced LHA from LGA	2 (6.5)	1 (3.2)	
Potal vein anatomy 0.530 Type 1 27 (87.1) 29 (93.5) Type 2 3 (9.7) 2 (6.5) Type 3 1 (3.2) 0 (0.0) Bile duct anatomy 0.366 0 (0.0) Type 1 25 (80.6) 28 (90.3) Type 2 2 (6.5) 0 (0.0) Type 3b 3 (9.7) 3 (9.7) Type 4b 1 (3.2) 0 (0.0) Cold ischemic time, minutes 42.2 ± 19.1 50.2 ± 24.1 0.156 Warm ischemic time, minutes 5.5 ± 1.8 6.8 ± 3.6 0.518 Total ischemic time, minutes 28 (90.3) 30 (96.8) 2 0.00 2 3 (9.7) 1 (3.2) 0.001 0.988 1 2.2 0.058 1 28 (90.3) 29 (93.5) 2 0.001 0.988 1 0.988 1 0.988 1 0.021 0.001 1.52 0.001 1.52 0.001 1.52 0.001 1.52 0.001 1.52 0.001 1.52 0.001	Accessory LHA from LGA	0 (0.0)	0 (0.0)	
Type 1 27 (87.1) 29 (93.5) Type 2 3 (9.7) 2 (6.5) Type 3 0.000 0.000 Bile duct anatomy 0.000 0.000 Type 1 25 (80.6) 28 (90.3) Type 2 2 (6.5) 0 (0.0) Type 3b 3 (9.7) 3 (9.7) Type 4b 1 (3.2) 0 (0.0) Cold ischemic time, minutes 25 ± 18.1 6.8 ± 3.6 0.518 Total ischemic time, minutes 72.1 ± 20.4 81.3 ± 23.2 0.105 Number of arteries 72.1 ± 20.4 81.3 ± 23.2 0.105 Number of oble duct openings 72.1 ± 20.4 81.3 ± 23.2 0.105 1 28 (90.3) 30 (96.8) 1 0.508 2 3 (9.7) 1 (3.2) 0.001 1.4 28 (90.3) 30 (96.8) 1 0.146 Length of operation time 360.1 ± 58.3 383.0 ± 64.0 0.146 Length of operation time 360.1 ± 58.3 383.0 ± 64.0 0.146 Length of operation time <td>Portal vein anatomy</td> <td></td> <td></td> <td>0.530</td>	Portal vein anatomy			0.530
Type 2 3 (9.7) 2 (6.5) Type 3 1 (3.2) 0 (0.0) Bile duct anatomy 0.366 Type 1 25 (80.6) 28 (90.3) Type 2 2 (6.5) 0 (0.0) Type 3b 3 (9.7) 3 (9.7) Type 4b 1 (3.2) 0 (0.0) Cold ischemic time, minutes 42.2 ± 19.1 50.2 ± 24.1 0.156 Warm ischemic time, minutes 5.5 ± 1.8 6.8 ± 3.6 0.518 Total ischemic time, minutes 5.5 ± 1.8 6.8 ± 3.6 0.518 Total ischemic time, minutes 72.1 ± 20.4 81.3 ± 23.2 0.105 Number of arteries 0.508 0.518 0.518 1 28 (90.3) 30 (96.8) 0.508 2 3 (9.7) 1 (3.2) 0.508 1 28 (90.3) 30 (96.8) 0.516 2 3 (9.7) 2 (6.5) 0.518 Length of portation time 360.1 ± 58.3 383.0 ± 64.0 0.146 Length of postoperative hospital stay, days 10.6 ± 1.6 <td< td=""><td>Туре 1</td><td>27 (87.1)</td><td>29 (93.5)</td><td></td></td<>	Туре 1	27 (87.1)	29 (93.5)	
Type 3 1 (3.2) 0 (0.0) Bile duct anatomy 0.366 Type 1 25 (80.6) 28 (90.3) Type 2 2 (6.5) 0 (0.0) Type 3b 3 (9.7) 3 (9.7) Type 4b 1 (3.2) 0 (0.0) Cold ischemic time, minutes 42.2 ± 19.1 50.2 ± 24.1 0.156 Warm ischemic time, minutes* 5.5 ± 1.8 6.8 ± 3.6 0.518 Total ischemic time, minutes* 72.1 ± 20.4 81.3 ± 23.2 0.105 Number of arteries 72.1 ± 20.4 81.3 ± 23.2 0.105 Number of arteries 72.1 ± 20.4 81.3 ± 23.2 0.105 Number of bile duct openings 72.1 ± 20.4 81.3 ± 23.2 0.105 2 3 (9.7) 1 (3.2) 0.988 1 2 0.988 1 28 (90.3) 29 (93.5) 2 0.146 1.64 1.64 1.64 1.64 1.64 1.64 1.64 1.64 1.64 1.64 1.64 1.64 1.64 1.64 1.64 1.64 </td <td>Туре 2</td> <td>3 (9.7)</td> <td>2 (6.5)</td> <td></td>	Туре 2	3 (9.7)	2 (6.5)	
Bile duct anatomy 0.366 Type 1 25 (80.6) 28 (90.3) Type 2 2 (6.5) 0 (0.0) Type 3b 3 (9.7) 3 (9.7) Type 4b 1 (3.2) 0 (0.0) Cold ischemic time, minutes 42.2 ± 19.1 50.2 ± 24.1 0.156 Warm ischemic time, minutes 72.1 ± 20.4 81.3 ± 23.2 0.105 Number of arteries 72.1 ± 20.4 81.3 ± 23.2 0.105 Number of arteries 72.1 ± 20.4 81.3 ± 23.2 0.105 Number of bile duct openings 72.1 ± 20.4 81.3 ± 23.2 0.105 1 28 (90.3) 30 (96.8) 2 0.508 1 28 (90.3) 30 (96.8) 2 0.508 1 28 (90.3) 29 (93.5) 2 0.146 Length of operation time 360.1 ± 58.3 383.0 ± 64.0 0.146 Length of opstoperative hospital stay, days 10.6 ± 1.6 8.1 ± 2.7 <0.001	Туре 3	1 (3.2)	0 (0.0)	
Type 1 25 (80.6) 28 (90.3) Type 2 2 (6.5) 0 (0.0) Type 3b 3 (9.7) 3 (9.7) Type 4b 1 (3.2) 0 (0.0) Cold ischemic time, minutes 42.2 ± 19.1 50.2 ± 24.1 0.156 Warm ischemic time, minutes* 5.5 ± 1.8 6.8 ± 3.6 0.518 Total ischemic time, minutes 72.1 ± 20.4 81.3 ± 23.2 0.105 Number of arteries 0.508 30 (96.8) 0.58 1 28 (90.3) 30 (96.8) 0.58 2 3 (9.7) 1 (3.2) 0.05 Number of bile duct openings 2 3 (9.7) 2 (6.5) Length of operation time 360.1 ± 58.3 383.0 ± 64.0 0.146 Length of operation time 360.1 ± 58.3 383.0 ± 64.0 0.146 Length of operation time 1 (3.2) 0 (0.0) 0.152 Wound problem 1 (3.2) 0 (0.0) 0.152 Wound problem 1 (3.2) 0 (0.0) 1.52 Pleural effusion 1 (3.2) 0	Bile duct anatomy			0.366
Type 2 2 (6.5) 0 (0.0) Type 3b 3 (9.7) 3 (9.7) Type 4b 1 (3.2) 0 (0.0) Cold ischemic time, minutes 42.2 ± 19.1 50.2 ± 24.1 0.156 Warm ischemic time, minutes* 5.5 ± 1.8 6.8 ± 3.6 0.518 Total ischemic time, minutes* 7.2 1 ± 20.4 81.3 ± 23.2 0.105 Number of arteries	Туре 1	25 (80.6)	28 (90.3)	
Type 3b 3 (9.7) 3 (9.7) Type 4b 1 (3.2) 0 (0.0) Cold ischemic time, minutes 42.2 ± 19.1 50.2 ± 24.1 0.156 Warm ischemic time, minutes* 5.5 ± 1.8 6.8 ± 3.6 0.518 Total ischemic time, minutes* 72.1 ± 20.4 81.3 ± 23.2 0.105 Number of arteries 72.1 ± 20.4 81.3 ± 23.2 0.105 Number of arteries 28 (90.3) 30 (96.8) 0.588 1 28 (90.3) 30 (96.8) 0.988 2 3 (9.7) 1 (3.2) 0.988 1 28 (90.3) 29 (93.5) 0.988 2 3 (9.7) 2 (6.5) 0.146 Length of operation time 360.1 ± 58.3 383.0 ± 64.0 0.146 Length of operation time 360.1 ± 58.3 383.0 ± 64.0 0.146 Length of operation time 1 (3.2) 0 (0.0) 0.152 Wound problem 1 (3.2) 0 (0.0) 0.152 Pleual effusion 1 (3.2) 0 (0.0) 0.152 Pleual effu	Туре 2	2 (6.5)	0 (0.0)	
Type 4b 1 (3.2) 0 (0.0) Cold ischemic time, minutes 42.2 ± 19.1 50.2 ± 24.1 0.156 Warm ischemic time, minutes* 5.5 ± 1.8 6.8 ± 3.6 0.518 Total ischemic time, minutes 72.1 ± 20.4 81.3 ± 23.2 0.105 Number of arteries 72.1 ± 20.4 81.3 ± 23.2 0.105 Number of arteries 0.508 30 (96.8) 0.508 1 28 (90.3) 30 (96.8) 0.988 1 28 (90.3) 29 (93.5) 0.988 1 28 (90.3) 29 (93.5) 0.988 1 28 (90.3) 29 (93.5) 0.146 Length of operation time 360.1 ± 58.3 383.0 ± 64.0 0.146 Length of operation time 360.1 ± 58.3 383.0 ± 64.0 0.146 Length of postoperative hospital stay, days 10.6 ± 1.6 8.1 ± 2.7 <0.001	Туре Зb	3 (9.7)	3 (9.7)	
Cold ischemic time, minutes 42.2 ± 19.1 50.2 ± 24.1 0.156 Warm ischemic time, minutes* 5.5 ± 1.8 6.8 ± 3.6 0.518 Total ischemic time, minutes 72.1 ± 20.4 81.3 ± 23.2 0.105 Number of arteries 0.508 0.908 0.908 1 $28 (90.3)$ $30 (96.8)$ 0.988 2 $3 (9.7)$ $1 (3.2)$ 0.988 1 $28 (90.3)$ $29 (93.5)$ 0.988 2 $3 (9.7)$ $2 (6.5)$ 0.146 Length of operation time 360.1 ± 58.3 383.0 ± 64.0 0.146 Length of postoperative hospital stay, days 10.6 ± 1.6 8.1 ± 2.7 <0.001 Surgical complication $1 (3.2)$ $0 (0.0)$ 0.152 Wound problem $1 (3.2)$ $0 (0.0)$ 0.00 Bile leakage $0 (0.0)$ $0 (0.0)$ $0 (0.0)$ Pleural effusion $1 (3.2)$ $0 (0.0)$ $0 (0.0)$ None $28 (94.4)$ $31 (100.0)$ $0 (0.0)$	Type 4b	1 (3.2)	0 (0.0)	
Warm ischemic time, minutes* 5.5 ± 1.8 6.8 ± 3.6 0.518 Total ischemic time, minutes 72.1 ± 20.4 81.3 ± 23.2 0.105 Number of arteries 0.508 0.105 0.508 2 3 (9.7) 1 (3.2) 0.105 Number of bile duct openings 28 (90.3) 30 (96.8) 0.708 1 28 (90.3) 29 (93.5) 0.708 2 3 (9.7) 2 (6.5) 0.146 Length of operation time 360.1 ± 58.3 383.0 ± 64.0 0.146 Length of postoperative hospital stay, days 10.6 ± 1.6 8.1 ± 2.7 <0.001	Cold ischemic time, minutes	42.2 ± 19.1	50.2 ± 24.1	0.156
Total ischemic time, minutes 72.1 ± 20.4 81.3 ± 23.2 0.105 Number of arteries 0.508 0.508 1 28 (90.3) 30 (96.8) 0.05 2 3 (9.7) 1 (3.2) 0.088 1 28 (90.3) 29 (93.5) 0.055 2 3 (9.7) 2 (6.5) 0.146 Length of operation time 360.1 ± 58.3 383.0 ± 64.0 0.146 Length of operation time 360.1 ± 58.3 383.0 ± 64.0 0.146 Length of postoperative hospital stay, days 10.6 ± 1.6 8.1 ± 2.7 <0.001	Warm ischemic time, minutes*	5.5 ± 1.8	6.8 ± 3.6	0.518
Number of arteries 0.508 1 28 (90.3) 30 (96.8) 2 3 (9.7) 1 (3.2) Number of bile duct openings 0.988 1 28 (90.3) 29 (93.5) 2 3 (9.7) 2 (6.5) Length of operation time 360.1 ± 58.3 383.0 ± 64.0 0.146 Length of postoperative hospital stay, days 10.6 ± 1.6 8.1 ± 2.7 <0.001	Total ischemic time, minutes	72.1 ± 20.4	81.3 ± 23.2	0.105
1 28 (90.3) 30 (96.8) 2 3 (9.7) 1 (3.2) Number of bile duct openings 0.988 1 28 (90.3) 29 (93.5) 2 3 (9.7) 2 (6.5) Length of operation time 360.1 ± 58.3 383.0 ± 64.0 0.146 Length of postoperative hospital stay, days 10.6 ± 1.6 8.1 ± 2.7 <0.001	Number of arteries			0.508
2 3 (9.7) 1 (3.2) Number of bile duct openings 0.988 1 28 (90.3) 29 (93.5) 2 3 (9.7) 2 (6.5) Length of operation time 360.1 ± 58.3 383.0 ± 64.0 0.146 Length of postoperative hospital stay, days 10.6 ± 1.6 8.1 ± 2.7 <0.001	1	28 (90.3)	30 (96.8)	
Number of bile duct openings 0.988 1 28 (90.3) 29 (93.5) 2 3 (9.7) 2 (6.5) Length of operation time 360.1 ± 58.3 383.0 ± 64.0 0.146 Length of postoperative hospital stay, days 10.6 ± 1.6 8.1 ± 2.7 <0.001	2	3 (9.7)	1 (3.2)	
1 28 (90.3) 29 (93.5) 2 3 (9.7) 2 (6.5) Length of operation time 360.1 ± 58.3 383.0 ± 64.0 0.146 Length of postoperative hospital stay, days 10.6 ± 1.6 8.1 ± 2.7 <0.001	Number of bile duct openings			0.988
2 3 (9.7) 2 (6.5) Length of operation time 360.1 ± 58.3 383.0 ± 64.0 0.146 Length of postoperative hospital stay, days 10.6 ± 1.6 8.1 ± 2.7 <0.001	1	28 (90.3)	29 (93.5)	
Length of operation time 360.1 ± 58.3 383.0 ± 64.0 0.146 Length of postoperative hospital stay, days 10.6 ± 1.6 8.1 ± 2.7 <0.001 Surgical complication 0.16 ± 1.6 8.1 ± 2.7 <0.001 Wound problem $1 (3.2)$ $0 (0.0)$ $0 (0.0)$ Bile leakage $0 (0.0)$ $0 (0.0)$ $0 (0.0)$ Pleural effusion $1 (3.2)$ $0 (0.0)$ $0 (0.0)$ Fluid collection $1 (3.2)$ $0 (0.0)$ $0 (0.0)$ None $28 (90.4)$ $31 (100.0)$ $0 (0.0)$ Clavien-Dindo classification 1 0 0 Grades 1 and 2 1 0 0 2 0 0 0	2	3 (9.7)	2 (6.5)	
Length of postoperative hospital stay, days 10.6 ± 1.6 8.1 ± 2.7 <0.001	Length of operation time	360.1 ± 58.3	383.0 ± 64.0	0.146
Surgical complication 0.152 Wound problem 1 (3.2) 0 (0.0) Bile leakage 0 (0.0) 0 (0.0) Pleural effusion 1 (3.2) 0 (0.0) Fluid collection 1 (3.2) 0 (0.0) None 28 (90.4) 31 (100.0) Clavien-Dindo classification 1 0 Grades 1 and 2 1 0 Grades 3 and 4 2 0	Length of postoperative hospital stay, days	10.6 ± 1.6	8.1 ± 2.7	<0.001
Wound problem 1 (3.2) 0 (0.0) Bile leakage 0 (0.0) 0 (0.0) Pleural effusion 1 (3.2) 0 (0.0) Fluid collection 1 (3.2) 0 (0.0) None 28 (90.4) 31 (100.0) Clavien-Dindo classification	Surgical complication			0.152
Bile leakage 0 (0.0) 0 (0.0) Pleural effusion 1 (3.2) 0 (0.0) Fluid collection 1 (3.2) 0 (0.0) None 28 (90.4) 31 (100.0) Clavien-Dindo classification 0 0 Grades 1 and 2 1 0 Grades 3 and 4 2 0	Wound problem	1 (3.2)	0 (0.0)	
Pleural effusion 1 (3.2) 0 (0.0) Fluid collection 1 (3.2) 0 (0.0) None 28 (90.4) 31 (100.0) Clavien-Dindo classification 31 (100.0) Grades 1 and 2 1 0 Grades 3 and 4 2 0	Bile leakage	0 (0.0)	0 (0.0)	
Fluid collection 1 (3.2) 0 (0.0) None 28 (90.4) 31 (100.0) Clavien-Dindo classification 7 0 Grades 1 and 2 1 0 Grades 3 and 4 2 0	Pleural effusion	1 (3.2)	0 (0.0)	
None 28 (90.4) 31 (100.0) Clavien-Dindo classification 0 0 Grades 1 and 2 1 0 Grades 3 and 4 2 0	Fluid collection	1 (3.2)	0 (0.0)	
Clavien-Dindo classification0Grades 1 and 210Grades 3 and 420	None	28 (90.4)	31 (100.0)	
Grades 1 and 2 1 0 Grades 3 and 4 2 0	Clavien-Dindo classification			
Grades 3 and 4 2 0	Grades 1 and 2	1	0	
	Grades 3 and 4	2	0	

TABLE 4. Perioperative and Postoperative Surgical Outcomes of Donors and Grafts After PSM

NOTE: Data are provided as n (%) or mean \pm standard deviation.

*The time to retrieve a graft from the abdomen.

of hepatic venous outflow obstruction (HVOO). The ideal techniques for hepatic vein anastomosis minimize the possibility of the vein acting as an axis for torsion. Tannuri et al.⁽²¹⁾ changed their techniques to a large longitudinal incision on the recipient inferior vena cava after the closure of the hepatic vein orifice to create a widely patent anastomosis. Fukuda et al.⁽²²⁾ proposed a modified triangular technique and



FIG. 2. Operative photographs of left hepatic vein venoplasty. Two openings were identified and unified (A and B). Additional crossing septotomy can be performed to deepen the common channel portion, and patch venoplasty is performed using a cold-preserved fresh iliac vein patch (C and D).

reported no incidence of HVOO in 122 patients who received transplants with this technique. Our center also performs patchplasty routinely to ensure a wide opening and proper vein height using cold-preserved fresh iliac vein tissue at the recipient and graft sides. This procedure also aids in the ease of the surgical procedure by securing the field of anastomosis. This venoplasty is particularly useful when an anomaly is present in the left hepatic vein of the donor (Fig. 2).

In our study, HVOOs did not occur in the laparoscopic technique group, which is a reasonable outcome compared with that in other studies. The surgical outcome data, including the overall survival rate of the recipients, showed no significant difference between the open and laparoscopic technique groups. These results suggest that the laparoscopic technique did not adversely affect the outcome of the recipients.

The secure division of the bile duct is also an important factor associated with complications on the donor and recipient sides. For safe bile duct division, cholangiography using C-arm and indocyanine green fluorescence imaging are the most representative modalities used. Our institute prefers to use cholangiography because it not only captures images but also enables a bile leak test using methylene blue injected through the cholangiography tube.

Lastly, some authors argue that the laparoscopic environment represented by carbon dioxide pneumoperitoneum adversely affects the living donor graft in cases of kidney transplantation⁽²³⁻²⁴⁾; however, we identified that it did not adversely affect any clinical outcome, including the long-term survival of recipients and graft rejection rates.

At the Second International Consensus Conference on laparoscopic liver resection held in October 2014 in Morioka, Japan, laparoscopic donor hepatectomy for pediatric LDLT was categorized as IDEAL 2b according to the Balliol group classification.⁽²⁵⁾

The IDEAL freamwork, a model for the implementation of surgery with defined stages for innovation of a pariticular surgical technique. IDEAL comprises Idea (stage 1), Development (stage 2a), Exploration (stage 2b), Assessment (stage 3), and Long-term study (stage 4).

On the basis of the research in our institute and other studies so far, we agree with this level of recommendation and expect to progress to laparoscopic minor hepatic resection (IDEAL 3).

Several limitations of our study must be addressed. As a single-center study, this study was limited to center-specific populations and treatment practices. From the indications and donor anatomies described in Tables 1 and 2, more open approaches have been implemented in cases of fulminant hepatic failure and complex donor anatomical characteristics. In other words, although no special exclusion criteria were used for the study period, some selection bias was present. Furthermore, the retrospective nature of our study limited our ability to directly control for confounding variables that could have affected the outcomes despite performing PSM.

In conclusion, on the basis of the analysis of 100 cases of pediatric LDLT, the laparoscopic approach does not increase the donor operation time as compared with the open approach and is associated with shorter postoperative hospital stays. The surgical approach (open versus laparoscopic) does not influence the ischemic time and surgical complication rates in donors or recipients. The present study shows that laparoscopic left lateral donor hepatectomy could be beneficial for the donor and that the use of the laparoscopic technique in donors does not adversely affect the long-term outcomes of the recipients. Thus, laparoscopic left lateral sectionectomy for the living donor is a safe, feasible, and reproducible procedure for pediatric liver transplantation.

REFERENCES

- Feier FH, Chapchap P, Pugliese R, da Fonseca ES, Carnevale FC, Moreira AM, et al. Diagnosis and management of biliary complications in pediatric living donor liver transplant recipients. Liver Transpl 2014;20:882-892.
- Scatton O, Katsanos G, Boillot O, Goumard C, Bernard D, Stenard F, et al. Pure laparoscopic left lateral sectionectomy in living donors: from innovation to development in France. Ann Surg 2015;261:506-512.
- Broering DC, Berardi G, El Sheikh Y, Spagnoli A, Troisi RI. Learning curve under proctorship of pure laparoscopic living donor left lateral sectionectomy for pediatric transplantation. Ann Surg 2020;271:542-548.
- Soubrane O, Cherqui D, Scatton O, Stenard F, Bernard D, Branchereau S, et al. Laparoscopic left lateral sectionectomy in living donors: safety and reproducibility of the technique in a single center. Ann Surg 2006;244:815-820.

- Chang S, Laurent A, Tayar C, Karoui M, Cherqui D. Laparoscopy as a routine approach for left lateral sectionectomy. Br J Surg 2007;94:58-63.
- Troisi R, Debruyne R, Rogiers X. Laparoscopic living donor hepatectomy for pediatric liver transplantation. Acta Chir Belg 2009;109:559-562.
- Cherqui D, Soubrane O, Husson E, Barshasz E, Vignaux O, Ghimouz M, et al. Laparoscopic living donor hepatectomy for liver transplantation in children. Lancet 2002;359:392-396.
- 8) Koch M, Garden OJ, Padbury R, Rahbari NN, Adam R, Capussotti L, et al. Bile leakage after hepatobiliary and pancreatic surgery: a definition and grading of severity by the International Study Group of Liver Surgery (ISGLS). Surgery 2011;149:680-688.
- Kim KH, Jung DH, Park KM, Lee YJ, Kim DY, Kim KM, Lee SG. Comparison of open and laparoscopic live donor left lateral sectionectomy. Br J Surg 2011;98:1302-1308.
- 10) Kim KH, Kang SH, Jung DH, Kim WJ, Yoon YI, Lee SG, et al. Initial outcomes of pure laparoscopic living donor right hepatectomy in an experienced adult living donor liver transplant center. Transplantation 2017;101:1106-1110.
- 11) Coelho FF, Bernardo WM, Kruger JAP, Jeismann VB, Fonseca GM, et al. Laparoscopy-assisted versus open and pure laparoscopic approach for liver resection and living donor hepatectomy: a systematic review and meta-analysis. HPB (Oxford) 2018;20:687-694.
- 12) Macacari RL, Coelho FF, Bernardo WM, Kruger JAP, Jeismann VB, Fonseca GM, et al. Laparoscopic vs. open left lateral sectionectomy: an update meta-analysis of randomized and nonrandomized controlled trials. Int J Surg 2019;61:1-10.
- 13) Samstein B, Griesemer A, Halazun K, Kato T, Guarrera JV, Cherqui D, Emond JC. Pure laparoscopic donor hepatectomies: ready for widespread adoption? Ann Surg 2018;268:602-609.
- 14) Wakabayashi G, Nitta H, Takahara T, Shimazu M, Kitajima M, Sasaki A. Standardization of basic skills for laparoscopic liver surgery towards laparoscopic donor hepatectomy. J Hepatobiliary Pancreat Surg 2009;16:439-444.
- 15) Yu YD, Kim KH, Jung DH, Lee S-G, Kim Y-G, Hwang G-S. Laparoscopic liver donor left lateral sectionectomy is safe and feasible for pediatric living donor liver transplantation. Hepatogastroenterology 2012;59:2445-2449.
- Park JI, Kim KH, Lee SG. Laparoscopic living donor hepatectomy: a review of current status. J Hepatobiliary Pancreat Sci 2015;22:779-788.
- 17) Miura K, Sakamoto S, Shimata K, Honda M, Kobayashi T, Wakai T, et al. The outcomes of pediatric liver retransplantation from a living donor: a 17-year single-center experience. Surg Today 2017;47:1405-1414.
- 18) Kang SH, Namgoong JM, Hwang S, Jung D-H, Kim K-M. Wedged-patch venoplasty of the left liver graft portal vein for size matching in pediatric living donor liver transplantation. Ann Hepatobiliary Pancreat Surg 2019;23:183-186.
- 19) Soubrane O, de Rougemont O, Kim KH, Samstein B, Mamode N, Boillot O, et al. Laparoscopic living donor left lateral sectionectomy: a new standard practice for donor hepatectomy. Ann Surg 2015;262:757-763; discussion 761-763.
- 20) Broering DC, Elsheikh Y, Shagrani M, Abaalkhail F, Troisi RI. Pure laparoscopic living donor left lateral sectionectomy in pediatric transplantation: a propensity score analysis on 220 consecutive patients. Liver Transpl 2018;24:1019-1030.
- Tannuri U, Tannuri AC, Santos MM, Miyatani HT. Technique advance to avoid hepatic venous outflow obstruction in pediatric livingdonor liver transplantation. Pediatr Transplant 2015;19:261-266.
- 22) Fukuda A, Sakamoto S, Shigeta T, Uchida H, Hamano I, Sasaki K, et al. Clinical outcomes and evaluation of the quality of life of living donors for pediatric liver transplantation: a single-center analysis of 100 donors. Transplant Proc 2014;46:1371-1376.

- 23) Troppmann C, Ormond DB, Perez RV. Laparoscopic (vs open) live donor nephrectomy: a UNOS database analysis of early graft function and survival. Am J Transplant 2003;3:1295-1301.
- 24) Wever KE, Bruintjes MH, Warle MC, Hooijmans CR. Renal perfusion and function during pneumoperitoneum: a systematic review and meta-analysis of animal studies. PLoS One 2016;11: e0163419.
- 25) Wakabayashi G, Cherqui D, Geller D, Buell JF, Kaneko H, Han HS, et al. Recommendations for laparoscopic liver resection: a report from the second international consensus conference held in Morioka. Ann Surg 2015;261:619-629.
- 26) Varotti G, Gondolesi G, Goldman J, WayneWayne M, Florman SS, Schwartz ME, et al. Anatomic variations in right liver living donors. J Am Coll Surg 2004;198:577-582.